AstraZeneca has been granted a patent for methods and compositions to treat or prevent Respiratory Syncytial Virus (RSV) infection. The patent includes a single fixed dose regimen of an anti-RSV monoclonal antibody, nirsevimab, tailored to the patient’s weight and age, particularly for high-risk infants. GlobalData’s report on AstraZeneca gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AstraZeneca, Personalized cancer vaccines was a key innovation area identified from patents. AstraZeneca's grant share as of June 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
Methods for preventing rsv infection using monoclonal antibodies
The patent US12024553B2 outlines a method for preventing Respiratory Syncytial Virus (RSV) lower respiratory tract infection (LRTI) through the administration of a single fixed dose of an anti-RSV monoclonal antibody or its antigen-binding fragment. The claims specify that the antibody must contain particular variable regions defined by specific sequences (SEQ ID NOs). The dosage is tailored based on the subject's weight and age, with distinct dosages of 50 mg, 100 mg, or 200 mg recommended for subjects under 5 kg, those weighing 5 kg, and high-risk individuals in their second year of life, respectively. High-risk subjects may include those with chronic lung disease, congenital heart disease, Down's Syndrome, or immunodeficiencies.
Additionally, the patent details the composition of the pharmaceutical formulation, which includes specific concentrations of ionic excipients, buffers, sugars, and surfactants, ensuring a pH range of 5.5 to 6.5. The method emphasizes the importance of maintaining serum concentrations of the monoclonal antibody, nirsevimab, above a specified threshold to effectively prevent RSV LRTI. Administration is recommended to occur intramuscularly at the onset of the RSV season, and the method may be combined with other agents, including antiviral medications, to enhance efficacy. The claims collectively aim to provide a targeted approach to RSV prevention in vulnerable populations, particularly infants and young children.
To know more about GlobalData’s detailed insights on AstraZeneca, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
